Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021

HomeBioMarker StrategiesKorean Patent Office Grants New Patent Covering PathMAP® Functional Signaling Profile Technology

Korean Patent Office Grants New Patent Covering PathMAP® Functional Signaling Profile Technology

“Compositions and Methods for Prediction of Drug Sensitivity, Resistance, and Disease Progression” (KR10-1977875) for PathMAP® Functional Signaling Profile technology

“PathMAP Functional Signaling Profiles are highly predictive of individual solid tumor responses to targeted therapies and combinations because they are based on the dynamic, predictive signaling information available only from live cells,” said Jerry Parrott, President and CEO, BioMarker Strategies.

PathMAP Functional Signaling Profiles are made possible by the Company’s proprietary SnapPath® Cancer Diagnostics System, which was developed specifically to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers. SnapPath is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. The system preserves the molecular integrity of these living cells for ex vivo exposure to targeted therapies on the SnapPath System. The Korean Patent Office previously granted a patent covering the Company’s SnapPath® Cancer Diagnostics System technology in 2018.

“Patents on both of our core technologies have now been gr

anted in the United States, Europe, Australia, Canada, Japan and Korea,” said Mr. Parrott. “These and other granted patents give us broad protection to advance our mission to enable the use of live cells to personalize drug development and treatment selection for patients with solid tumor cancers.”

Patents Granted BioMarker Strategies for Its SnapPath® Cancer Diagnostics System: “Improved Methods and Devices for Cellular Analysis”


Patent #

Issue Date


United States US9121801 September 1, 2015 December 28, 2030
Europe EP2210080 January 28, 2015 October 24, 2028
Australia AU2008317329 January 15, 2015 October 24, 2028
Australia AU2014277688 January 19, 2017 October 24, 2028



August 22, 2017

October 24, 2028

Hong Kong HK1145878

August 14, 2015

October 24, 2028

Japan JP6177841 July 21, 2017 October 24, 2028
Korea KR10-1658245 September 9, 2016 October 24, 2028

Patents Granted for the Company’s PathMAP® Functional Signaling Profile Technology: “Compositions for Prediction of Drug Sensitivity, Resistance and Disease Progression”*


Patent #

Issue Date


United States US9766249 September 19, 2017 August 31, 2025
Europe EP2561368 August 2, 2017 April 18, 2031
Australia AU2011242990 May 28, 2015 April 18, 2031
Canada CA2795362 March 20, 2018 April 18, 2031



April 13, 2018 April 18, 2031
Japan JP6158078 June 16, 2017 April 18, 2031
Korea KR10-1977875 May 7, 2019 April 18, 2031
Singapore SG184507 May 6, 2015 April 18, 2031

The SnapPath and PathMAP technologies are ideally suited to assess response to targeted drugs and combinations, including combinations with Immunotherapies, in development for the treatment of solid tumor cancers.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy